Adtech company OpenX sues Google, accusing it of anticompetitive tactics that 'crippled' its growth
The adtech company alleged that Google's tactics "crippled competitors like OpenX at every turn."
A federal judge has ruled Google holds an illegal monopoly in advertising technology markets.
Adtech company OpenX has accused Google of repeatedly kneecapping its growth through anticompetitive tactics in the digital advertising market — and now it wants payback.
OpenX on Monday piggybacked on an antitrust lawsuit previously filed against Google by the US Department of Justice with a lawsuit of its own.
The supply-side platform's 88-page lawsuit, filed in the US District Court for the Eastern District of Virginia, said that the tech behemoth's illegal business practices "crippled competitors like OpenX at every turn," making it impossible for them to compete on a "level playing field."
Google, the company alleged in its lawsuit, targeted OpenX and used its dominance in the online ad space "to rig the rules by which digital advertising is bought and sold, to the detriment of OpenX and the entire industry."
OpenX alleged in its complaint that Google's conduct has "stifled innovation, harmed competition, decreased product quality and caused significant damage to OpenX, as well as to Google's own publisher and advertiser customers."
Google did not immediately respond to a request for comment by Business Insider.
OpenX's lawsuit comes less than four months after a federal judge in the same court ruled that Google holds an illegal monopoly in certain online advertising technology markets.
The April ruling followed a trial that stemmed from a DOJ lawsuit, which argued that Google used acquisitions and anticompetitive ad auction tactics to build an illegal monopoly of the digital ad market.
Judge Leonie Brinkema found Google liable for monopolizing the publisher ad servers and ad exchange markets. OpenX appears to be the first adtech company to bring a related lawsuit against Google since Brinkema's ruling.
Google owns an ad server that publishers use to manage their inventory, buying tools that advertisers use to purchase ads, and an ad exchange that connects the two. The judge said that the combination of its ad server and ad exchange gave Google significant control over which ads appear on websites.
The court could potentially force a breakup of Google's adtech business. Google plans to appeal the judge's ruling. (The remedies portion of the trial is set to begin on September 22.)
"Now that the Court has found Google's conduct to be illegal and anticompetitive, this lawsuit seeks to recover damages for the harm caused to us and our shareholders — and to help ensure fair competition going forward," OpenX CEO John Gentry said in a statement.
OpenX's lawsuit said that the California-based company, founded in 2008, has only a small percentage of the multibillion-dollar ad exchange market and that its publisher ad server "was driven out of the market by Google's conduct" and shut down in 2019.
"Among other things, Google has coerced publishers not to work with OpenX through illegal tying arrangements, exploited its monopolies to rig digital advertising auctions so that OpenX wins fewer transactions, and steered advertiser dollars that Google controls away from OpenX and towards Google's own ad exchange, all while concealing much of its conduct from both OpenX and Google's own advertising customers," the lawsuit said.
The lawsuit seeks a jury trial, an unspecified amount in damages, and an injunction "prohibiting Google's anticompetitive conduct."
Read the original article on Business Insider
Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi
We recently published . Hudbay Minerals Inc. (NYSE:HBM) is one of the best-performing stocks on Wednesday. Hudbay Minerals grew its share prices for a second day on Wednesday, up 15.03 percent to close at $11.33 apiece, following an impressive earnings performance and a $600-million investment from Mitsubishi Corp. In its updated report, Hudbay Minerals Inc. (NYSE:HBM) said it swung to a net income attributable to shareholders of $117.7 million from an attributable net loss of $16.5 million in the same period last year, driven by higher gross margins and strong cost control. Revenues increased by 26 percent to $536.4 million from $425.5 million year-on-year. 'With the strong performance in the first half of the year, we are reaffirming our full year consolidated production guidance and are favourably tracking well below our full year consolidated cost guidance for 2025,' said Hudbay Minerals Inc. (NYSE:HBM) President and CEO Peter Kukielski. For the full-year period, the company is targeting to produce between 117,000 and 149,000 tons of copper, as well as 247,500 to 308,000 ounces of gold. In other news, Hudbay Minerals Inc. (NYSE:HBM) was able to raise $600 million in fresh funds from Mitsubishi Corp. after the latter acquired a 30-percent stake in Copper World LLC. Under the agreement, Mitsubishi will pay an upfront cash of $420 million, with the balance to serve as a matching contribution within an 18-month period. While we acknowledge the potential of HBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
